TRAF7 mutations in adenomatoid tumors
doi:10.1038/modpathol.2017.153
To investigate the molecular pathogenesis of adenomatoid tumors, Goode et al used genomic profiling on a cohort of 31 such tumors of the male and female genital tracts. All harbored somatic missense mutations in the five distinct hotspots in the C-terminally encoded WD40 repeats of TRAF7, an E3 ubiquitin ligase in the tumor necrosis factor receptor-associated factor (TRAF) family. TRAF7 mutations were shown in vitro to drive aberrant NF-κB pathway activation. With documentation to support the fact that immune dysregulation may contribute to the development of these tumors, the group hypothesized that this could be due to selective pressure for the acquisition of activating TRAF7 mutations or to potentiate the oncogenic effect of the mutations once acquired. The finding that all these tumors were defined by a set of mutations in the same gene, functionally driving the same pathway, provides a clear target for future study with regard to classification and therapeutic intervention. 
Clonality in bilateral serous

Immune landscapes influence tumor progression
Bezzi et al investigated how immune states of the tumor microenvironment influence progression and metastasis through immunosuppression. Using Pten-loss prostate cancer as a model, either alone or in combination with loss of Trp53, Zbtb7a, or Pml, they identified distinct heterogeneity in these infiltrated landscapes. Zbtb7a transcriptionally represses granulocyte attractant CXCL5, which is upregulated in Pten pc−/− ; Zbtb7a p−/− tumors, whereas loss of p53 leads to upregulated expression of Gr-1 + CD11b cell attractant CXCL17. Assessing these different genetic backgrounds revealed distinct patterns of immune cell distribution, ranging from barren to heavy infiltration. These observations were supported by analysis of human prostate cancer specimens. The group proposes that successful clinical trials and precision therapeutics for these cancers will be designed only by taking genotypicimmunophenotypic analyses into account. 2018; 24:165-175; doi:10.1038/nm.4463 Vaccines to prevent antimicrobial resistance
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The morbidity and mortality associated with the rise in antimicrobial resistance due to bacterial pathogens have reached alarming levels. Effective immunization can reduce the use of antibiotics and, even with such use, can slow the associated rise in antimicrobial resistance. Strategies currently under development by the World Health Organization to combat antimicrobial resistance encompass a range of modalities. In the assessment of Jansen et al, vaccines are an underrecognized resource despite documented successes. The influenza vaccine, for example, is known to combat not only influenza but other secondary bacterial infections, such as pneumonia and otitis media, indicating that the expensive and long-term work that goes into establishing new vaccines, in addition to being necessary in its own right, can lead to protection against antimicrobial resistance. Vaccine development is one side of the global issue; the other side is maintaining and creating new markets to ensure commercial viability. 2018;24:10-19; doi:10.1038/nm.4465 Emma Judson contributed to these reviews. 
